Then, we examined whether the expression of CMTM6 or PD-L1, coexpression of CMTM6 and PD-L1, or expression of CMTM6 in ICs (CD4+, CD8+, CD68+ and CD163+) could predict the responsiveness to PD-1/PD-L1 inhibitors in CRC patients. This evidence concerns the gene CD68 and colorectal carcinoma.